Literature DB >> 11750246

Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia.

M J Barry1.   

Abstract

Benign prostatic hyperplasia (BPH) is a common histologic condition among older men, which conveys its morbidity through lower urinary tract symptoms and complications, such as acute urinary retention, obstructive uropathy, and urinary tract infections. The mechanisms linking the histologic process and lower urinary tract symptoms remain uncertain; prostatic enlargement and bladder outlet obstruction are involved. However, measurements of prostate size and the severity of bladder outlet obstruction correlate poorly with the severity of lower urinary tract symptoms. The severity of lower urinary tract symptoms associated with BPH can be measured reliably, from the patient's perspective, with a number of validated questionnaires, including the International Prostate Symptom Score, the Danish Prostate Symptom Score, and the International Continence Society (ICS)male questionnaire. In the clinical setting, these questionnaires can be used (1) to assess the severity of symptoms in men with lower urinary tract symptoms that may be attributable to BPH, based on their age and clinical characteristics; and (2) to follow changes in symptoms over time and with treatment. None of these questionnaires can accurately determine whether a symptomatic patient has underlying bladder outlet obstruction. Additional questionnaires are available to measure the impact of lower urinary tract symptoms on men's lives, as well as associated phenomena, such as continence and sexual function, which may be affected by BPH and its treatments. Men with a severe burden of lower urinary tract symptoms often have measurable decrements in overall health-related quality of life, which can be ameliorated by treatment.

Entities:  

Mesh:

Year:  2001        PMID: 11750246     DOI: 10.1016/s0090-4295(01)01300-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  32 in total

Review 1.  Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life.

Authors:  Donald MacDonald; Thomas A McNicholas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  How important are men's lower urinary tract symptoms (LUTS) and their impact on the quality of life (QOL)?

Authors:  J Haltbakk; B R Hanestad; S Hunskaar
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

3.  Associations of carotid artery plaque with lower urinary tract symptoms and erectile dysfunction.

Authors:  Jun Ho Lee; Soon Ki Kim; Dong-Gi Lee
Journal:  Int Urol Nephrol       Date:  2014-09-12       Impact factor: 2.370

4.  Factors that influence lower urinary tract symptom (LUTS)-related quality of life (QoL) in a healthy population.

Authors:  Woo Suk Choi; Nam Ju Heo; Young Ju Lee; Hwancheol Son
Journal:  World J Urol       Date:  2017-06-05       Impact factor: 4.226

5.  The change of IPSS 7 (nocturia) score has the maximum influence on the change of Qol score in patients with lower urinary tract symptoms.

Authors:  Woo Suk Choi; Hwancheol Son
Journal:  World J Urol       Date:  2018-08-02       Impact factor: 4.226

Review 6.  Measurement of benign prostatic hyperplasia treatment effects on male sexual function.

Authors:  T A Skolarus; J T Wei
Journal:  Int J Impot Res       Date:  2009-06-18       Impact factor: 2.896

7.  Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).

Authors:  Kuo-Pao Lai; Chiung-Kuei Huang; Lei-Ya Fang; Kouji Izumi; Chi-Wen Lo; Ronald Wood; Jon Kindblom; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Endocrinol       Date:  2013-07-26

8.  Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer.

Authors:  Shibao Li; Zhiyuan Wu; Yuming Chen; Zhihua Kang; Hua Wang; Ping He; Xinju Zhang; Tingting Hu; Qunfeng Zhang; Yanqun Cai; Xiao Xu; Ming Guan
Journal:  Tumour Biol       Date:  2015-11-11

9.  Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.

Authors:  João Silva; Rui Pinto; Tiago Carvalho; Francisco Botelho; Pedro Silva; Rui Oliveira; Carlos Silva; Francisco Cruz; Paulo Dinis
Journal:  BMC Urol       Date:  2009-08-15       Impact factor: 2.264

10.  Construction and validation of a short-form quality-of-life scale for chinese patients with benign prostatic hyperplasia.

Authors:  Yanfang Guo; Jingcheng Shi; Ming Hu; Zhenqiu Sun
Journal:  Health Qual Life Outcomes       Date:  2009-03-17       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.